# US 8,278,033 B2 · Efficient well being assessment and improved treatment protocol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,033 B2
- Document ID: US8278033B2
- Status: Granted
- Kind: B2
- Application number: 12/994,105
- Filed: 2009-05-22
- Published: 2011-07-14
- Granted: 2012-10-02
- Earliest claimed: 2008-05-22
- Inventors: Larry Mark Weisenthal
- Web page: https://patentgrep.com/patent/US8278033B2

## CPC

- G01N 33/52: Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper {and including single- and multilayer analytical elements (immunological elements G01N33/54386; involving labelled immunochemicals G01N33/58; for haemoglobin or occult blood G01N33/72)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 2510/00: Detection of programmed cell death, i.e. apoptosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods to appraise general health and to assess the effectiveness of therapeutic agents are disclosed. These methods can be performed on blood samples or other bodily fluids and comprise effecting cell death of endothelial cells, staining the dead cells and observing them microscopically. In addition, the invention is directed to combination treatments for neoplastic diseases or other conditions characterized by unwanted angiogenesis by administering an antiangiogenesis agent while maintaining nontoxic levels of ethanol and/or DMSO in the blood.

## Claims

### Claim 1

A method to detect and optionally quantify circulating endothelial cells in a vertebrate subject which method comprises
(a) contacting body fluid that contains circulating cells obtained from said subject with an antiangiogenic agent so as to render living endothelial cells nonviable;
(b) treating the cells with a dye that is excluded by viable cells but taken up by dead cells; and
(c) observing the resulting cells under a microscope, and
(d) identifying the nonviable endothelial cells in said fluid by their dye-staining, size of about one third that of lymphocytes, angular appearance and intense and refractile color,
wherein the body fluid is blood, lymph or plasma.

### Claim 2 (depends on 1)

The method of claim 1 wherein the dye is Fast Green.

### Claim 3 (depends on 1)

The method of claim 1 wherein the cells are further treated with a dye that stains viable cells.

### Claim 4 (depends on 3)

The method of claim 3 wherein said dye that stains viable cells is hematoxylin/eosin (H&E) or Wright-Giemsa.

### Claim 5 (depends on 1)

The method of claim 1 which further comprises quantifying the endothelial cells.

### Claim 6 (depends on 1)

The method of claim 1 wherein the body fluid is blood or plasma.

### Claim 7 (depends on 1)

A method to assess the effectiveness of a therapeutic agent which method comprises comparing the level of circulating endothelial cells in the blood, lymph or plasma of a test subject treated with said agent with either
(i) the level of circulating endothelial cells in the blood, lymph or plasma of said subject prior to treating said agent; or
(ii) the level of circulating endothelial cells in the blood, lymph or plasma of a control subject not treated with said agent;
whereby a decreased level of circulating endothelial cells in the blood, lymph or plasma of said test subject as compared to that in the blood, lymph or plasma of the subject of subparagraphs (i) or (ii) is indicative of effectiveness of said agent, and wherein said assessment is conducted by the method of claim 1.

### Claim 8

A method to detect and optionally quantify endothelial cells in a tissue which method comprises
(a) disaggregating said tissue to obtain a sample that includes any endothelial cells contained therein,
(b) treating the sample with an antiangiogenic agent to render living endothelial cells nonviable;
(c) treating the sample with a dye that is excluded by viable cells but taken up by dead cells; and
(d) observing the cells in the sample under a microscope, and
(e) identifying the nonviable endothelial cells in said sample by their dye-staining, size of about one third that of lymphocytes, angular appearance and intense and refractile color.

### Claim 9 (depends on 8)

The method of claim 8 wherein said antiangiogenic agent is bevacizumab.

### Claim 10 (depends on 8)

The method of claim 8 wherein the dye is Fast Green.

### Claim 11 (depends on 8)

The method of claim 8 wherein the cells are further treated with a dye that stains viable cells.

### Claim 12 (depends on 11)

The method of claim 11 wherein said dye that stains viable cells is hematoxylin/eosin (H&E) or Wright-Giemsa.

### Claim 13 (depends on 8)

The method of claim 8 which further comprises quantifying the endothelial cells.

### Claim 14

A method to determine the effect of a treatment on viability of endothelial cells in a tissue, which method compromises
(a) contacting said tissue comprised of at least viable endothelial cells and natively surrounding viable non-endothelial cells with said treatment to be tested for its effect on endothelial cell viability,
(b) if necessary, disaggregating the tissue to obtain a sample containing any endothelial cells without effecting any additional endothelial cell death,
(c) treating the sample with a dye that is excluded by viable cells but taken up by dead cells;
(d) observing the resulting cells under a microscope, and
(e) identifying the nonviable endothelial cells in said sample by their dye-staining, size of about one third that of lymphocytes, angular appearance and intense and refractile color.

### Claim 15 (depends on 14)

The method of claim 14 wherein the dye is Fast Green.

### Claim 16 (depends on 14)

The method of claim 14 wherein the cells are further treated with a dye that stains viable cells.

### Claim 17 (depends on 16)

The method of claim 16 wherein said dye that stains viable cells is hematoxylin/eosin (H&E) or Wright-Giemsa.
